MDAI Research | Milton Maxwell

MDAI

Spectral AI, Inc.

1.5000

+0.0100+0.67%

Dec 16, 4:00:02 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

46.03M

P/E (TTM)

Basic EPS (TTM)

-0.75

Dividend Yield

Recent Filings

8-K

Capone named Spectral AI CEO

2/10/26Feb 10, 2026

Spectral AI appointed Vincent S. Capone as CEO effective February 9, 2026, dissolving the Office of the Chairman. The internal promotion from CFO and General Counsel positions Capone to steer commercialization of the DeepView burn wound system post its June 2025 FDA submission. Board praises his finance-law blend. Compensation pending.

8-K

CCO Sparks exits abruptly

2/3/26Feb 3, 2026

Spectral AI's Chief Commercial Officer Jeremiah Sparks stepped down February 1, 2026, to pursue other opportunities, with no disagreements on operations. Smooth transition intact. He signed a 90-day consulting deal at $4,000 weekly. National search underway for replacement.

8-K

Director resigns cleanly

1/6/26Jan 6, 2026

Spectral AI director Colin Bristow resigned effective January 5, 2026. No disagreements with company operations, policies, or practices triggered the exit. Board now slims down quietly.

10-Q

Q3 FY2025 results

11/13/25Nov 13, 2025

Spectral AI's Q3 revenue fell 53.6% y/y to $3.8M from BARDA contracts, yet gross margin held at 42.7% while operating loss widened to $3.3M on higher G&A. Cash climbed to $10.5M, bolstered by $8.5M Avenue debt (prime +5.25%, due 2028) and equity raises; net loss trailed operating by $211K due to interest and borrowing costs. Debt stands at $7.8M. Shares outstanding doubled y/y, diluting EPS to $(0.13). FDA De Novo filed June 2025. Revenue hinges on U.S. government contracts. Material weaknesses flagged in controls.

8-K

Spectral AI raises $7.6M

10/24/25Oct 24, 2025

Spectral AI closed a $7.6M registered direct offering on October 24, 2025, selling 3,065,000 common shares at $1.90 each plus concurrent private warrants for 4M shares at $2.51 exercise price and pre-funded warrants for 935,000 shares. Northland Securities earned a 6% fee; proceeds target working capital. Warrants need stockholder approval by June 2026, or quarterly thereafter.

About

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient's wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.

CEO

Dr. John Michael DiMaio M.D.

IPO

4/6/2021

Website

https://www.spectral-ai.com

Employees

Sector

Healthcare

Industry

Medical Devices